Skip to main content
. 2019 May 9;24(3):220–226. doi: 10.1097/MOT.0000000000000629

Table 1.

Anti-HLA antibody detection methods

graphic file with name cootr-24-220-i001.jpg
Method CDC (LCT) FCM PRA (solid-phase assay)
Target Donor lymphocytes Donor lymphocytes Purified HLA antigens
Antibody specificity Donor-specific complement-binding antibodies Donor-specific complement-binding/nonbinding antibodies Known HLA antibodies Non-HLA antibodies
Sensitivity Low Detects only complement-binding antibodies High Detects both complement-binding and nonbinding antibodies High Detects both complement-binding and nonbinding antibodies
Effects of medications Influenced by cytotoxic antibodies (ATG, rituximab, and so on) Influenced by antibody therapies (high-dose IVIG, ATG, rituximab) Influenced by antibody therapies (high-dose IVIG, ATG, rituximab)

ATG, Antithymocyte globulin; CDC, complement-dependent cytotoxicity; FCM, flow cytometry crossmatching; IVIG, intravenous immunoglobulin; LCT, lymphocyte cytotoxicity test; PRA, panel-reactive antibody.